If you have been NEWLY DIAGNOSED START HERE
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate...
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate...
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate...
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding...
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding...
From the GRACE Archives - Originally Published April 11, 2009 | By Dr Pennell
From the GRACE Archives - Originally Published November 21, 2009 | By Dr. Weiss
I’ve been impressed by many things about GRACE and its members. Among these many things are the thirst for new information and better treatments. I also admire the openness of the members both to new ideas, and to questioning these ideas.
From the GRACE Archives -- Originally Published August 28, 2011 | By Dr. West
From the GRACE Archives | Originally Published March 17, 2012 | By Dr West
From the GRACE Archives--Originally Published November 2, 2007 | By Dr West
Or “What I Say vs. What I Do”
Hi, I hope someone from this great community can help. My mom was diagnosed with Stage 4 NSCLC 3.5 years ago. At the time of diagnosis she tested positive for EGFR l858r and was subsequently put on Tarceva which lasted a little over a year before she progressed. Went on Tagrisso for about 1.5 years. She recently tried carbo/alimpta/Keytruda but discontinued in March this year since she was still progressing after 3 rounds.
In the following series of videos, faculty discuss therapeutic options for triple-negative breast cancer. Topics discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.
In the following series of videos, faculty discuss therapeutic options for triple-negative breast cancer. Topics discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.
In the following series of videos, faculty discuss therapeutic options for triple-negative breast cancer. Topics discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock